12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Metamark Genetics, J&J deal

Johnson & Johnson's Janssen Biotech Inc. unit partnered with Metamark to identify cancer targets using Metamark's Prognosis Determinant discovery technology. Janssen can select targets for exclusive licensing...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >